Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes.
Zhang Y, Tan W, Wang X, Zheng X, Huang Y, Li B, Meng Z, Gao Y, Qian Z, Liu F, Lu X, Shi Y, Shang J, Yan H, Zheng Y, Zhang W, Gu W, Qiao L, Deng G, Zhou Y, Hou Y, Zhang Q, Xiong S, Liu J, Duan L, Chen R, Chen J, Jiang X, Luo S, Chen Y, Jiang C, Zhao J, Ji L, Mei X, Li J, Li T, Zheng R, Zhou X, Ren H, Cheng X, Guo L, Li H; Chinese (Acute on) Chronic Liver Failure Consortium (Ch-CLIF.C).
Zhang Y, et al.
J Hepatol. 2023 Nov;79(5):1159-1171. doi: 10.1016/j.jhep.2023.07.011. Epub 2023 Jul 29.
J Hepatol. 2023.
PMID: 37517452